CAS Number54965-24-1
Synonymstrans-2-(p-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate; EINECS 259-415-2; Tamoxifen, citrate salt; MFCD00058321; Tamoxifen citrate salt; 2YR&UYR&R DO2N1&1 &&Z Form citrate; Tamoxifen citrate; Tamoxifen (Citrate)
Molecular FormulaC32H37NO8
Molecular Weight371.51 (salt-free basis)
Purity≥99 (HPLC)%
Boiling Point665.9ºC at 760 mmHg
Melting Point140-144 °C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 54965-24-1 |
| Catalog No. | 2A-9011693 |
| Chinese Name | 枸橼酸他莫昔芬 |
| Synonyms | trans-2-(p-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate; EINECS 259-415-2; Tamoxifen, citrate salt; MFCD00058321; Tamoxifen citrate salt; 2YR&UYR&R DO2N1&1 &&Z Form citrate; Tamoxifen citrate; Tamoxifen (Citrate) |
| Molecular Formula | C32H37NO8 |
| Molecular Weight | 371.51 (salt-free basis) |
| Purity | ≥99 (HPLC) |
| Boiling Point | 665.9ºC at 760 mmHg |
| Melting Point | 140-144 °C |
| Appearance | powder |
| Water Solubility | slightly soluble |
| Storage Condition | Sealed, stored at 2ºC -8ºC |
| Application | Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). |
| HTC | 2922199090 |
| MDL Number | MFCD00058321 |
| SMILES | N(CCOc1ccc(cc1)\C(=C(\CC)/c3ccccc3)\c2ccccc2)(C)C.[O-]C(=O)C(O)(CC(=O)[O-])CC(=O)[O-].[H+].[H+].[H+] |
| InChI | 1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; |
| InChI Key | FQZYTYWMLGAPFJ-OQKDUQJOSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/11693_1_54965_24_1.pdf |
| Bioactivity | Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Cancer Target Estrogen receptor[1] In Vitro Tamoxifen shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2]. In Vivo The Tamoxifen-inducible gene knockout strategy has clear advantages in that expression of a gene can be ablated in adult mice at will in a tissue specific manner. To study the role of Med1 in adult heart, 7-week old TmcsMed1-/- mice are given a daily Iintraperitoneal injection of Tamoxifen at a dose of 65 mg/kg for 5 days and killed at selected intervals thereafter. qPCR analysis of RNA shows that the Med1 expression begin to decrease after 3 days of Tamoxifen injection (about 70% decrease), and by 5 days of injection, Med1 expression is almost non-detectable in the heart. Tamoxifen-inducible cardiac-specific disruption of Med1 (TmcsMed1-/-) in adult mice causes dilated cardiomyopathy[3]. Animal Admin Mice[3] Seven-week old TmcsMed1-/- mice and the wild-type littermates are then administered Tamoxifen intraperitoneally at a daily dose of 65 mg/kg body weight for 5 days and then killed at selected intervals after initiation of Tamoxifen treatment. For each experiment 3 to 5 mice for control and csMed1-/- are used. To obtain survival curve 41 csMed1-/- and 41 csMed1fl/fl mice are used. Thirteen TmcsMed-/- mice and the same number of littermates are used for the survival curve experiments using Tamoxifen inducible model. The specific criteria for animal euthanasia included absence of food or water intake, slow or no mobility, weak or absence of heart beat, absence of palpitation of the chest as well as absence of respiratory movement. Mice are euthanized by intraperitoneal pentobarbital injection at the dose of 150mg/kg body weight to minimize suffering. References [1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. Chemical & Physical Properties Boiling Point 665.9ºC at 760 mmHg Melting Point 140-144 °C Molecular Formula C32H37NO8 Molecular Weight 563.638 Flash Point 356.5ºC Exact Mass 563.251892 PSA 144.60000 LogP 4.74760 InChIKey FQZYTYWMLGAPFJ-OQKDUQJOSA-N SMILES CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O Storage condition 2-8°C Water Solubility slightly soluble |
| Use of | Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). Properties Articles161 Name tamoxifen citrate Synonym More Synonyms Tamoxifen citrate Biological Activity Description Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Cancer Estrogen receptor[1] References [1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. Chemical & Physical Properties Molecular Formula C32H37NO8 Exact Mass 563.251892 PSA 144.60000 LogP 4.74760 InChIKey FQZYTYWMLGAPFJ-OQKDUQJOSA-N Water Solubility slightly soluble |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 30.0% |
| Transport Info | Product name: Purity: 99.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available See reverse side of invoice or packing slip. |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Nelfinavir mesylate | 159989-64-7 | 2A-9011605 |
| Nevirapine | 129618-40-2 | 2A-9011622 |
| Nifedipine | 21829-25-4 | 2A-9011652 |
| Nimodipine | 66085-59-4 | 2A-9011671 |
| Noctone; Ranitidine Hydrochloride | 71130-06-8 | 2A-9011688 |
| Norbuprenorphine | 78715-23-8 | 2A-9011701 |
| Norclomipramine | 2A-302786 | 2A-9011703 |
| Norcodeine hydrochloride | 14648-14-7 | 2A-9011704 |
| Nordiazepam | 1088-11-5 | 2A-9011705 |
| Norfloxacin nicotinate | 118803-81-9 | 2A-9011710 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS